These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23803372)

  • 1. Maintenance treatment of mild gastroesophageal reflux disease with proton pump inhibitors taken on-demand: a meta-analysis.
    Jiang YX; Chen Y; Kong X; Tong YL; Xu SC
    Hepatogastroenterology; 2013; 60(125):1077-82. PubMed ID: 23803372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
    Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
    J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
    Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
    Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
    Vakil NB; Huff FJ; Bian A; Jones DS; Stamler D
    Am J Gastroenterol; 2011 Aug; 106(8):1427-38. PubMed ID: 21519360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.
    Bytzer P; Jones R; Vakil N; Junghard O; Lind T; Wernersson B; Dent J
    Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1360-6. PubMed ID: 22813439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease.
    Tjon JA; Pe M; Soscia J; Mahant S
    Pharmacotherapy; 2013 Sep; 33(9):956-71. PubMed ID: 23712734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
    Johnson DA; Katz PO
    Rev Gastroenterol Disord; 2008; 8(2):98-108. PubMed ID: 18641592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
    van der Pol RJ; Smits MJ; van Wijk MP; Omari TI; Tabbers MM; Benninga MA
    Pediatrics; 2011 May; 127(5):925-35. PubMed ID: 21464183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily.
    Gasiorowska A; Navarro-Rodriguez T; Wendel C; Krupinski E; Perry ZH; Koenig K; Moty B; Powers J; Fass R
    Am J Gastroenterol; 2009 Aug; 104(8):2005-13. PubMed ID: 19491829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
    Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
    J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.
    Boeckxstaens GE; Beaumont H; Hatlebakk JG; Silberg DG; Björck K; Karlsson M; Denison H
    Gut; 2011 Sep; 60(9):1182-8. PubMed ID: 21402616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.
    Tonini M; Vigneri S; Neri M; Cuomo R; Savarino V; Pace F
    Digestion; 2007; 76(3-4):171-8. PubMed ID: 18046084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease.
    Kahrilas PJ; Howden CW; Hughes N
    Am J Gastroenterol; 2011 Aug; 106(8):1419-25; quiz 1426. PubMed ID: 21537361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.
    Shaheen NJ; Denison H; Björck K; Karlsson M; Silberg DG
    Gut; 2013 Sep; 62(9):1248-55. PubMed ID: 22730470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'.
    Pace F; Tonini M; Pallotta S; Molteni P; Porro GB
    Aliment Pharmacol Ther; 2007 Jul; 26(2):195-204. PubMed ID: 17593065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabeprazole 10 mg versus 20 mg in preventing relapse of gastroesophageal reflux disease: a meta-analysis.
    Zhu HD; Wang H; Xia XM; Xu SM; Lan Y
    Chin Med J (Engl); 2013 Aug; 126(16):3146-50. PubMed ID: 23981627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis.
    Chan WW; Chiou E; Obstein KL; Tignor AS; Whitlock TL
    Arch Intern Med; 2011 Apr; 171(7):620-9. PubMed ID: 21482834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.
    Orenstein SR; Hassall E; Furmaga-Jablonska W; Atkinson S; Raanan M
    J Pediatr; 2009 Apr; 154(4):514-520.e4. PubMed ID: 19054529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.